Rosen Law Firm reminds purchasers of ADMA Biologics securities between August 9, 2024 and March 25, 2026 of the August 10, 2026 lead plaintiff deadline in a securities class action first filed by the firm. Investors with losses exceeding $100,000 are encouraged to secure counsel before the deadline. The lawsuit alleges that ADMA Biologics made materially false and misleading statements and failed to disclose an undisclosed related party transaction, channel stuffing to inflate revenue, and inadequate internal controls. When the true details entered the market, investors allegedly suffered damages. The firm notes that it achieved the largest ever securities class action settlement against a Chinese company and has recovered billions of dollars for investors.
ADMA Biologics IncSecurities class action lawsuit alleges false statements and undisclosed related party transaction, channel stuffing, and inadequate internal controls.